Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Sylvie Moureau, Craig MacKay, Chiara Saladino, Elizabeth Pohler, Karin Kroboth, Jonathan Hollick, Daniella Zheleva, Sheelagh Frame and David Blake | ||||||||||||
Title | The novel PLK1 inhibitor, CYC140: Identification of pharmacodynamic markers, sensitive target indications and potential combinations | ||||||||||||
|
|||||||||||||
URL | https://cancerres.aacrjournals.org/content/77/13_Supplement/4178 | ||||||||||||
Abstract Text | Cancer Res 2017;77(13 Suppl):Abstract nr 4178 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CYC140 | CYC 140|CYC-140 | PLK1 Inhibitor 18 | CYC140 is an ATP-competitive inhibitor of Plk1, which may lead to cell cycle arrest and inhibition of tumor cell growth (Cancer Res 2017;77(13 Suppl):Abstract nr 4178). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|